Survival rates are higher for stage IV NSCLC patients who are eligible for either targeted therapy or immunotherapy regimens, which increased overall survival from 10 to 24 months in those receiving EGFR- tyrosine kinase inhibitor (TKI) therapy versus those who did not [67–72]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.